Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3249923 | 0.74 | GBA1 (0.36) | MEN1KMT2AGBA1GAAHTT | |
| SCHEMBL27150194 | 0.71 | ROCK2 (0.43) | DAGLAFAAHGAAL3MBTL1MAPT | |
| SCHEMBL12819613 | 0.71 | GAA (0.45) | DAGLAFAAHMEN1KMT2AGBA1 | |
| SCHEMBL17371937 | 0.71 | MEN1 (0.50) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL1273108 | 0.71 | LMNA (0.42) | DAGLAFAAHGAALMNAMAPT | |
| SCHEMBL30759244 | 0.70 | LATS1 (0.46) | FAAHGAAALDH1A1HTTMAPT | |
| SCHEMBL28628837 | 0.70 | ALDH1A1 (0.39) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL20567938 | 0.70 | MEN1 (0.39) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL22075606 | 0.68 | LATS1 (0.49) | MEN1KMT2AGAALMNAALDH1A1 | |
| SCHEMBL1273107 | 0.68 | DAGLA (0.37) | DAGLAFAAHMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | DAGLA 3514/4885FAAH 1090/4885MEN1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.